Viewing nowCombinationTrusitam Extended Release Tablet 50/1000 mg (Sitagliptin, Metformin)
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boryung Co., Ltd.

MFDS item code 202202022 · Approved 2022.05.13 · Insurance code 641908160
Improvement of glycemic control in type 2 diabetes mellitus
This medication helps control blood glucose levels in patients with type 2 diabetes by using sitagliptin and metformin together. Taking this medication while maintaining a regular diet and exercise can help manage blood glucose more effectively. It stabilizes blood glucose levels and contributes to the prevention of complications. Therefore, this medication is very useful in the treatment of type 2 diabetes.
In antidiabetic therapy, the dose of this medicine should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. To reduce gastrointestinal adverse reactions caused by metformin, this medicine should be taken with a meal once daily, preferably in the evening, and the dose should be increased gradually. To maintain its extended-release properties, this medicine must be swallowed whole and must not be split, crushed, ground, or chewed. The 100/1000 mg extended-release tablets of this medicine are taken once daily, 1 tablet per dose. Patients taking the 50/500 mg or 50/1000 mg extended-release tablets of this medicine take 2 tablets together once daily. 1. Patients not currently receiving metformin treatment: For patients with no previous experience of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial total daily dose of this medicine is sitagliptin 100 mg and metformin 1000 mg. If adequate glycemic control cannot be achieved with the initial dose, the dose may be increased gradually up to the maximum recommended daily dose of metformin, 2000 mg, to reduce gastrointestinal adverse reactions caused by metformin. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine. 2. Patients receiving metformin treatment: For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is a total daily dose of sitagliptin 100 mg and the patient’s current metformin dose. Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. Patients who were receiving immediate-release tablets at a current metformin dose of 850 mg or 1000 mg twice daily may start with 2 tablets of this medicine 50/1000 mg extended-release tablets once daily. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial total daily dose of this medicine is sitagliptin 100 mg, and the initial dose of metformin should be determined based on the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia. Patients with renal impairment This medicine may be used in patients with moderate renal impairment stage 3a (creatinine clearance [CrCl] ≥ 45 and <60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and <60 mL/min/1.73m2) who do not have other symptoms that may increase the risk of lactic acidosis, with the following dosage adjustment. Treatment should not be initiated with this medicine because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 1000 mg daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl <45 mL/min or eGFR <45 mL/min/1.73m2, this medicine must be discontinued immediately.
This medication contains sitagliptin and metformin as treatments for diabetes, helping to regulate blood glucose levels. Sitagliptin may rarely cause serious allergic reactions; if skin rash, difficulty breathing, or facial swelling occurs within three months of taking, discontinue immediately and consult a doctor. Sitagliptin can cause acute pancreatitis; inform healthcare providers immediately if abdominal pain, nausea, or vomiting occurs. Metformin has a risk of causing lactic acidosis, so it should not be used in patients with impaired renal function, liver disease, severe infections, or dehydration. Patients with moderate to severe renal impairment, acute heart failure, acute myocardial infarction, or sepsis should not take this medication. This medication is not recommended for women who are pregnant or may become pregnant, breastfeeding mothers, or children under 18 years of age. While taking this medication, maintain regular meals and exercise, as symptoms of hypoglycemia such as dizziness, cold sweat, and tremors may occur. Particularly, when taken with other blood glucose-lowering agents or insulin, the risk of hypoglycemia may increase; therefore, dose adjustments should be made under a physician's guidance. Before and after administration of iodinated contrast media, this medication should be temporarily discontinued to avoid kidney stress and resumed only after confirming normal kidney function. Alcohol consumption may increase the risk of lactic acidosis, so patients should avoid excessive drinking while taking this medication. Moreover, it is important to regularly monitor kidney function and blood tests during this medication's use for any abnormalities. If a patient is facing surgery, or experiences severe infection or dehydration, this medication should be temporarily discontinued and resumed once the patient's condition stabilizes. Some patients may experience side effects such as diarrhea, headache, upper respiratory infection, abdominal pain; consult healthcare providers if symptoms are severe or persistent. Finally, this medication may not be fully absorbed, resulting in excretion in feces; if the medication is found in stool, inform a physician and check the status of blood glucose control.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent exposure to air or moisture, at room temperature between 1 degree and 30 degrees Celsius. Storing in this manner will help maintain its effectiveness for a longer time.
Bright green, bilaterally convex oval extended-release film-coated tablet
28 tablets/bottle, 56 tablets/bottle, 200 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boryung Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Shinil Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 113.4mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
GL Pharma Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Korea Hutech Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.